ArchiveSeptember 2016

NewsSpeak & PoliticalSpeak: NICED twice in one week

NICE turns down daclizumab for MSers on the NHS. #NewsSpeak #PoliticalSpeak #MSBlog NICE have just published their appraisal consultation document for daclizumab and have not recommended it on the NHS within its marketing authorisation for treating relapsing forms of multiple sclerosis in adults. This is depressing news and is not in the interests of MSers in England. I would not have expected...

ClinicSpeak: not so NICE – alemtuzumab vs. cladribine

NICE is not so NICE; alemtuzumab is too expensive to use properly. #ClinicSpeak #MSBlog #MSResearch Could oral cladribine steal alemtuzumab’s thunder? #ClinicSpeak #MSBlog #MSResearch I naively discovered yesterday that NHS England will only be allowing us to use two courses of alemtuzumb in our patients with active relapsing MS. If these patients breakthrough and need a third, fourth or...

Location, location, location: MS pathology preferentially affects the edges of the brain

The Paper Objective To assess the association between proximity to the inner (ventricular and aqueductal) and outer (pial) surfaces of the brain and the distribution of normal appearing white matter (NAWM) and grey matter (GM) abnormalities, and white matter (WM) lesions, in multiple sclerosis (MS). Methods 67 people with relapse-onset MS and 30 healthy controls were included in the...

How does laquinimod block attacks

Kaye J, Piryatinsky V, Birnberg T, Hingaly T, Raymond E, Kashi R, Amit-Romach E, Caballero IS, Towfic F, Ator MA, Rubinstein E, Laifenfeld D, Orbach A, Shinar D, Marantz Y, Grossman I, Knappertz V, Hayden MR, Laufer R. Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A. 2016. pii: 201607843. [Epub ahead of print]...

#GuestPost #ThinkHand, #ECTRIMS2016: Professor Coyle’s motion at the “Burning Debate”

Last week I posted my slides in favour of the motion that pwMS in wheelchairs should be included in DMT trials. You were asking to learn more about the motion against, and my opponent during the ‘burning debate’ at ECTRIMS 2016, Patricia Coyle, kindly agreed to share her slides and some key points of her argument for this Guestpost. Patricia K. Coyle, MD, FAAN, FANA, is...

Making Microglia

Muffat J, Li Y, Yuan B, Mitalipova M, Omer A, Corcoran S, Bakiasi G, Tsai LH, Aubourg P, Ransohoff RM, Jaenisch R. Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat Med. 2016. doi: 10.1038/nm.4189. [Epub ahead of print] Microglia, the only lifelong resident immune cells of the central nervous system (CNS), are highly specialized macrophages that have been...

#ClinicSpeak & #ThinkHand: Can I buy a 9-HPT?

How do you feel about paying for the cardboard 9-HPT? #ThinkHand #MSBlog #ClinicSpeak ‘Now that I can’t walk, my hands and arms have become my legs….’ a person with MS Since ECTRIMS our #ThinkHand campaign seems to be going viral. I am getting a steady stream of requests for the 9-HPT. I have had requests from organisations in the US and Ireland for large numbers of tests to be distributed to...

ClinicSpeak & NeuroSpeak: inviting MSers to ECTRIMS

It is essential that we start to invite MSers to attend ECTRIMS #ECTRIMS2016 #MSBlog #ClinicSpeak #NeuroSpeak “Last week I took flak from suggesting we should allow MSers to attend ECTRIMS so that they can attend scientific sessions, hold their own parallel sessions and submit posters. This is not a new idea and there are several well established precedents in many other disease areas. One...

EBV and smoking in MS: Two peas in a pod?

Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study Published online before print September 23, 2016, doi: 10.1177/1352458516671028 Kjetil Bjørnevik, Trond Riise,Inger Bostrom, llaria Casetta,Marianna Cortese,Enrico Granieri,Trygve Holmøy,Margitta T Kampman,Anne-Marie Landtblom,Sandra Magalhaes,Maura Pugliatti,Christina Wolfson,Kjell-Morten Myhr...

ResearchSpeak: ECTRIMS highlight ocrelizumab NEDA data

How important is rebaseling when assessing NEDA rates? Essential – just look at the stunning ocrelizumab NEDA data. #ECTRIMS2016 #ResearchSpeak #MSBlog “The poster below is another one of my ECTRIMS highlights. There is little doubt that ocrelizumab is a highly effective DMT. However, how does it perform if you treat-2-target of NEDA (T2T-NEDA)? I have been saying for sometime that to...

Translate

Categories

Recent Posts

Recent Comments

Archives